A research team at the University of Sheffield has secured funding to develop a monitoring system to assess a patient’s health and wellbeing based on their gait.
Comprising an array of small sensors, the technology is expected to be used to observe the effects of diseases such as Parkinson’s, chronic obstructive pulmonary disease (COPD), multiple sclerosis, proximal femoral fracture and congestive heart failure.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Poor gait is also linked to cognitive decline, dementia, higher risk of falls, greater disease risk and earlier death.
The €2.1m grant will be provided by the European Innovative Medicines Initiative 2 Joint Undertaking.
The research forms part of the European MOBILISE-D project, which aims to use digital technology to assess mobility loss while facilitating improved clinical trials and management.
Under the project, clinicians and scientists from academic centres in Europe will work with European Federation of Pharmaceutical Industries and Associations (EFPIA) member companies.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataA total of 34 organisations are participating in the research, including the Insigneo Institute, which is led by the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust.
The Insigneo Institute director and the university’s department of mechanical engineering professor Claudia Mazzà will lead the development of the digital monitoring technology.
Mazzà said: “MOBILISE-D is the product of a long-standing multidisciplinary collaboration between researchers at the Insigneo Institute for in silico Medicine and the NIHR Sheffield Biomedical Research Centre.
“It marks a fantastic opportunity for the University of Sheffield and Sheffield Teaching Hospital to contribute to a technology-based revolution in clinical management and personalised healthcare, with a local focus on multiple sclerosis.”
Sheffield Teaching Hospitals professor Basil Sharrack is set to lead the clinical validation of the technology in multiple sclerosis.
